The Mayo task force found no evidence from clinical trials to recommend treating people only on the basis of age in the absence of risk factors, high cholesterol or inflammation.* The ACC/AHA cholesterol treatment guideline recommends cholesterol-lowering medication as a primary preventive measure against cardiovascular disease, and encourages health care providers to simultaneously emphasize the importance of healthy lifestyle habits. Men this age will be classified as high risk only on the basis of age. * The ACC/AHA cholesterol treatment guideline recommends prescribing the strongest statins at high doses to most men older than 65, even those with no history of heart disease, or any major risk factor for heart attacks, and with normal cholesterol levels. Mayo’s cholesterol treatment recommendations challenge some core ACC/AHA recommendations, and go further in-depth in some areas. We agree with many points of the guideline, but there are some key areas where we do not completely agree or we wanted to expand and provide more guidance,” says Francisco Lopez-Jimenez, M.D., task force chairman and director of preventive cardiology at Mayo Clinic in Rochester, Minnesota. “The ACC/AHA cholesterol guideline was last updated in 2001, so it needed to be updated.
![dr iftikar kullo dr iftikar kullo](https://www.mayoclinic.org/-/media/kcms/employees/2018/06/16/22/35/marysia-tweet-15038271.jpg)
Mayo Clinic physicians are adopting the task force’s guideline.
![dr iftikar kullo dr iftikar kullo](https://mdxvitals-res.cloudinary.com/private_images/q_auto/professionals/1728121/photo.jpg)
Recommendations of the task force, made up of Mayo Clinic experts in cardiology, endocrinology and preventive medicine, with no conflicts of interest or links to the drug industry, will be published Aug. The task force concludes, based on current evidence, that not all patients encouraged to take cholesterol-lowering medications, such as statins, may benefit from them and that the guideline missed some important conditions that might benefit from medication.įurthermore, the task force believes an emphasis needs to be placed on an individualized treatment approach with each patient and exercising shared decision-making. Newswise - A Mayo Clinic task force challenges some recommendations in the updated guideline for cholesterol treatment unveiled by the American College of Cardiology (ACC) and American Heart Association (AHA) in 2013. News Research News Releases Journal News Medical News Science News Life News Business News Expert Pitch Google Fact Check Research Alert Marketplace News With Video/Audio Multimedia RSS Feeds byĬlick to watch video on Mayo Clinic News Network Whether this results in improved outcomes needs additional investigation.Latest News Coronavirus News Currently Embargoed Our findings suggest that disclosure of genetic risk of CHD together with conventional risk estimates is appreciated by patients. In conclusion, patients who received their genetic risk of CHD had higher PPC and tended to have higher GCS. Within both groups, PPC and GCS scores were similar in patients with or without family history (p = NS). In the CRS+GRS group, PPC and GCS scores were not correlated with GRS. A greater proportion of CRS+GRS participants had higher GCS scores (17.3 ± 5.3 vs 15.9 ± 6.3, p = 0.06).
![dr iftikar kullo dr iftikar kullo](https://d2uur722ua7fvv.cloudfront.net/photos/Dr-Tariq-Iftikhar-MD-246005-circle_large__v2__.png)
Participants who received CRS+GRS had higher PPC than those who received CRS alone although the absolute difference was small (25.2 ± 2.7 vs 24.1 ± 3.8, p = 0.04). Each participant subsequently met with a physician and then completed surveys to assess PPC and GCS. Risk estimates were disclosed by a genetic counselor who also reviewed how GRS altered risk in those randomized to CRS+GRS. Participants ( n = 207, age: 45–65 years) were randomized to receive estimated 10-year risk of CHD based on a conventional risk score (CRS) with or without a genetic risk score (GRS). We investigated whether disclosure of coronary heart disease (CHD) genetic risk influences perceived personal control (PPC) and genetic counseling satisfaction (GCS).